Autologous hematopoietic stem cell transplantation (aHSCT) has been used in multiple sclerosis (MS) for over two decades and is currently the fastest growing indication for this treatment in Europe. Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, discusses the guidelines and recommendations from European and American hematological and neurologic societies on using aHSCT in MS. Current evidence supports the use of aHSCT in highly active relapsing-remitting MS failing to respond to disease-modifying therapies. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.